Clinical Research Directory
Browse clinical research sites, groups, and studies.
FIBERGRAFT Aeridyan Posterolateral Fusion Study
Sponsor: DePuy Synthes Products, Inc.
Summary
This is a post-market, prospective, controlled, multicenter clinical study to evaluate radiographic fusion and clinical outcomes of FIBERGRAFT™ Aeridyan Matrix bone graft substitute in subjects who undergo a 1-3 level instrumented lumbar posterolateral fusion surgery. This clinical study will be conducted at up to 10 clinical sites within the United States.
Official title: A Post-market, Prospective, Controlled, Multicenter Clinical Study to Evaluate Radiographic Fusion of FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute in Subjects Who Undergo a Lumbar Posterolateral Fusion Surgery
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
316
Start Date
2025-08-15
Completion Date
2028-12-29
Last Updated
2026-02-13
Healthy Volunteers
No
Conditions
Interventions
FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute
FIBERGRAFT™ Aeridyan Matrix is a next generation synthetic bone graft that is resorbable, bioactive, and osteoconductive. FIBERGRAFT Aeridyan Matrix is composed of ultra-porous 45S5 bioactive glass granules, boron-based bioactive glass microspheres, and bovine type 1 collagen. The granules are made entirely of 45S5 bioactive glass fibers and feature a porous outer shell encasing an intricate nest of micro- and nano- fibers and microspheres. The nonporous microspheres are made entirely of boron-based bioactive glass and feature essential metallic ions such as zinc, copper, magnesium, and potassium. The highly biocompatible type 1 collagen5 serves as a carrier for the bioactive glass components. FIBERGRAFT Aeridyan Matrix is designed to have an adequate structural integrity for its application as a bone graft substitute material, while optimizing radiopacity and resorption.
Demineralized Bone Matrix
Demineralized Bone Matrix is to be used with bone marrow aspirate and mixed with autograft bone in accordance with approved indications per the IFU
Locations (7)
UC Davis Health System
Sacramento, California, United States
University Of Illinois
Chicago, Illinois, United States
UK Health Care Kentucky Neuroscience Institute
Lexington, Kentucky, United States
Brigham And Women's Hospital
Boston, Massachusetts, United States
Duke University Medical Center
Durham, North Carolina, United States
Rothman Orthopaedics Institute
Philadelphia, Pennsylvania, United States
UT Health Houston
Houston, Texas, United States